Generated: April 24, 2017
|Title:||Esylate and sulfate salts of R(+)-N-propargyl-1-aminoindan|
|Abstract:||The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.|
|Inventor(s):||Youdim; Moussa B. H. (Haifa, IL), Finberg; John P. M. (Tivon, IL), Levy; Ruth (Tel-Aviv, IL), Sterling; Jeffrey (Jerusalem, IL), Lerner; David (Jerusalem, IL), Yellin; Haim (Ramat-Gan, IL), Veinberg; Alex (Rehovot, IL)|
|Assignee:||Teva Pharmaceutical Industries Ltd. (N/A) Technion Research and Development Foundation, Ltd. (N/A)|
|Filing Date:||Jun 06, 1995|
|Claims:||1. Esylate salt of R(+)-N-propargyl-1-aminoindan. |
2. Sulfate salt of R(+)-N-propargyl-1-aminoindan.